Director, Allogeneic Hematopoietic Stem Cell Transplantation

University Health Network

Director, Allogeneic Hematopoietic Stem Cell Transplantation, Princess Margaret Cancer Centre, University Health Network

The Princess Margaret Cancer Centre is part of the University Health Network (UHN) and works together with Toronto General Hospital, Toronto Western Hospital, Princess Margaret Cancer Centre, and the Toronto Rehabilitation Institute as part of the larger research mission at UHN. We are the largest comprehensive cancer centre in Canada and considered one of the top 5 in the world. The Division of Medical Oncology and Hematology is the largest comprehensive program of its kind in Canada and dedicated to providing some of the most advanced and novel approaches to medical and hematologic oncology worldwide.

The Princess Margaret is currently expanding its Allogeneic Hematopoietic Stem Cell Transplantation (AlloHCT) Program and is seeking a Full-Time Director to provide leadership during an exciting period of growth and transformation. Our Program is the largest of its kind in Canada, currently performing ~130 related and unrelated donor allogeneic transplants per year, and targeted to more than double in size over the next three years. The Program is supported by two inpatient units, dedicated outpatient facilities, and a state-of-the-art GMP cell processing facility, which also supports the Autologous Transplant Program, as well as a widely-recognized transplantation program. Many opportunities for collaboration exist such as a close relationship between the transplant program and the leukemia site group, the latter being the largest program in Canada, and among the largest in North America.

As an international leader in the area of AlloHCT, the successful candidate will be appointed at the Associate or Full Professor level in the Department of Medicine at the University of Toronto, and will be a candidate for the Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation at the University Health Network. This Chair benefits from a $2 million endowment obtained through the generous support of Seymour Epstein’s $1 million gift and the work of The Princess Margaret Cancer Foundation.

The Director of AlloHCT sits within the Division of Medical Oncology and Hematology and reports directly to the Division Head. The Director is expected to coordinate the clinical and research activities of the AlloHCT group, as well as being involved in patient care, teaching, and research. The successful candidate must have a medical degree or equivalent and must be eligible for registration and appointment as an MD with the College of Physicians and Surgeons of Canada (or equivalent). The successful candidate must be able to function proficiently in English.  Compensation will depend on the amount of clinical work performed (estimate based on fee-for-service billings and other sources of compensation) but will be in the usual range for an experienced Allogeneic Stem Cell Transplant Physician in the Province of Ontario at approximately $300,000 to $365,000 per annum and commensurate with academic rank, qualifications, and experience. Signing bonuses and other opportunities are negotiable and determined on an individual basis. Health benefit options and plans are supplied per company policy. Candidate(s) may be reimbursed partial start-up costs with office expenses. 

Should you be interested in this opportunity, please forward your covering letter, curriculum vitae, and names and addressed of three referees to:

 Dr. Amit Oza - Chief, Division of Medical Oncology and Hematology

C/o Michelle Williams – Administrative Coordinator

Princess Margaret Cancer Centre, University Health Network

Suite 7-925, 700 University Avenue, Toronto, Ontario, Canada, M5G 1Z5

Office: 416.946.2341 Mobile: 647.642.4031

Fax: 416.946.2082 E-mail:

The deadline for application is October 08, 2018